Funded Biotechnology Startups in Baltimore
Across the 25 most recent Baltimore-area biotechnology rounds shown (from 2020-06-11 to 2026-05-01), the disclosed high is AsclepiX Therapeutics’ $35M on 2…
Across the 25 most recent Baltimore-area biotechnology rounds shown (from 2020-06-11 to 2026-05-01), the disclosed high is AsclepiX Therapeutics’ $35M on 2020-06-24, while the next-largest disclosed amounts are $34M (Delfi Diagnostics, 2025-12-18) and $31M (Vita Therapeutics, 2022-10-12). That makes the top disclosed rounds clustered in a similar “mid-$30Ms” band, rather than one clear single spike above the rest.
A concentration pattern appears in mid-to-late 2024: four entries with disclosed amounts fall between 2024-09-07 (CoapTech, $7M) and 2024-10-24 (Sonavex, $15M), including Rapafusyn Pharmaceuticals’ $28M on 2024-06-20. Stage and disclosure are also mixed: 17 of 25 rows are “Series Unknown” and 2 of 25 are explicitly “undisclosed” amounts (SereNeuro Therapeutics, 2026-05-01; Genesis Biotechnologies, 2026-04-01), with the most recent dated entry being SereNeuro Therapeutics on 2026-05-01.
Most recent rounds
25 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Baltimore biotech set, and how does it compare to the rest of the disclosed amounts?
The largest disclosed amount is AsclepiX Therapeutics at $35M (2020-06-24). The next-largest disclosed rounds sit very close in size: Delfi Diagnostics at $34M (2025-12-18) and Vita Therapeutics at $31M (2022-10-12), with other disclosed entries like Pearl Diagnostics’ $11M (2026-04-02) and Sonavex’ $15M (2024-10-24) below that band.
Are there temporal clusters in the most recent entries (e.g., a busy quarter)?
Yes. In late 2024, four disclosed rounds appear within about a month: Emit Imaging $5M (2024-10-03), CoapTech $7M (2024-09-07), MyMD $7M (2024-05-21) is outside that exact window but the main density is September–October with Previse $2M (2024-10-22), Sonavex $15M (2024-10-24), and Rapafusyn Pharmaceuticals’ $28M earlier in 2024 on 2024-06-20.
How dominant is “Series Unknown,” and does that change the usable comparison set for round sizes?
“Series Unknown” appears in 17 of 25 rows, which limits stage-based comparisons. Within the disclosed amounts, the size comparisons are still meaningful because only two rows are explicitly “undisclosed” (SereNeuro Therapeutics on 2026-05-01; Genesis Biotechnologies on 2026-04-01), while the rest use disclosed dollar amounts such as $34M (Delfi Diagnostics, 2025-12-18) and $31M (Vita Therapeutics, 2022-10-12).
Which stages show up as a smaller subset versus the many “Series Unknown” entries?
Outside “Series Unknown,” the visible stage labels are fewer and concentrated: Seed appears for Somnair ($4M, 2025-07-07) and Irazu Oncology ($500K, 2025-03-05); Series A appears for Sonavex ($15M, 2024-10-24) and Rapafusyn Pharmaceuticals ($28M, 2024-06-20); Series B appears for Vita Therapeutics ($31M, 2022-10-12). There are also “Non-equity Assistance” (xMD Diagnostics, 2022-07-06, undisclosed) and a Grant (Capsulomics $200K, 2021-11-22).
Are there outlier sizes worth flagging compared with the floor of disclosed amounts?
Yes. Kalocyte and Melatech both show the smallest disclosed amounts at $10K (2023-08-23), which is far below the top disclosed rounds (e.g., AsclepiX Therapeutics $35M on 2020-06-24). That spread suggests many rounds cluster in the $1M–$30M range (e.g., Pearl Diagnostics $11M on 2026-04-02 and CoapTech $7M on 2024-09-07) with a few very small disclosed events near the floor.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.